EGFR and non-small cell lung carcinoma: Although it has been observed that several NSCLC cell lines show relative resistance to ABT-737 monotherapy [33,34], ABT-737 significantly enhanced EGFR-TKI-induced cell killing of NSCLC, and thus, this combined treatment might be a promising new therapy [29].